Home/Pipeline/Undisclosed Multi-specific Antibodies

Undisclosed Multi-specific Antibodies

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Aakha Biologics

About Aakha Biologics

Aakha Biologics is a private, pre-clinical-stage biotech focused on revolutionizing immunotherapies for solid tumors through a novel platform for multi-specific antibodies. The company integrates multiple synergistic mechanisms into single molecules to efficiently target tumors and activate immune cells like T cells and NK cells. Backed by experienced leadership, a strong scientific advisory board, and strategic partnerships, Aakha has secured non-dilutive funding and entered into a licensing agreement to advance its pipeline. Its approach aims to address the significant unmet need in oncology by creating powerful, elegant therapeutic solutions for patients with limited options.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed